Our mission is to identify a suitable Strep A vaccine candidate for clinical development and progress it through early clinical trials in Australia.
We’ve scoped the global Strep A vaccine landscape and selected a lead vaccine candidate that met our criteria for development. We’re currently negotiating a partnership with the lead vaccine developer and preparing for clinical trials in 2022.
We’re firmly focused on demonstrating proof of concept in humans of the vaccine candidate and will establish partnerships for future clinical trials and vaccine licensure.
Our initial aim for the lead candidate will be to demonstrate the safe and effective prevention of Strep A-related pharyngitis.
Advancing a lead Strep A vaccine candidate through phase 1 and phase 2 efficacy trials along the clinical development pathway is a critical first step as recommended in the World Health Organisation vaccine development technology roadmap.
We aim to:
- Demonstrate safety and efficacy of the lead vaccine candidate for pharyngitis prevention in children living in urban Australia.
- Establish global partnerships to facilitate later stage clinical trials and licensure of the vaccine.
- Consult with Indigenous communities to increase the likelihood of Aboriginal Australians being among the first populations in the world to be the beneficiaries of a proven safe and effective Strep A vaccine.
Aboriginal and Torres Strait Islander peoples are referred to as Indigenous Australians throughout this website.